Ameriprise’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Ameriprise’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-796,865	Closed	-$4.78M	–	4082
2022 Q3	$4.78M	Buy	796,865 +39,380	+5%	+$223K	﹤0.01%	2262
2022 Q2	$3.14M	Buy	757,485 +5,108	+0.7%	+$18K	﹤0.01%	2589
2022 Q1	$2.86M	Buy	752,377 +50,273	+7%	+$227K	﹤0.01%	2751
2021 Q4	$3.16M	Sell	702,104 -68,390	-9%	-$347K	﹤0.01%	2763
2021 Q3	$3.59M	Buy	770,494 +124,304	+19%	+$658K	﹤0.01%	2604
2021 Q2	$4.56M	Buy	+646,190	New	+$3.48M	﹤0.01%	2515

Other funds holding STSA

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Ameriprise's STSA Position: Q4 2022 in Review

Ameriprise sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2022, closing a stake of 796,865 shares — an estimated $4.78M sold.

Ameriprise first reported a position in STSA in Q2 2021 and held it in 6 quarters. The position peaked at $4.78M in Q3 2022. 33 funds tracked by Wall St. Rank hold STSA as of Q4 2022.

Ameriprise reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Ameriprise sold 796,865 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $4.78M.
Ameriprise first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
Ameriprise's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $4.78M in Q3 2022.
33 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Ameriprise's 13F filing for Q4 2022, filed 14 Feb 2023.